Approval · Notice of Compliance 22847 · 2019
JAMP ELETRIPTAN: Notice of Compliance 22847
Issued November 4, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22847
- Date
- November 4, 2019
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- RELPAX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAMP ELETRIPTAN | 02493683 | Marketed |
| JAMP ELETRIPTAN | 02493691 | Marketed |
Medicinal ingredients
- ELETRIPTAN HYDROBROMIDE 20 MG per TAB
- ELETRIPTAN HYDROBROMIDE 40 MG per TAB